- Home
- BIIB vs FTV Comparison
BIIB vs FTV Comparison
Compare BIIB & FTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- FTV
- Stock Information
- Founded
- BIIB 1978
- FTV 2015
- Country
- BIIB United States
- FTV United States
- Employees
- BIIB N/A
- FTV N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- FTV Industrial Machinery/Components
- Sector
- BIIB Health Care
- FTV Industrials
- Exchange
- BIIB Nasdaq
- FTV Nasdaq
- Market Cap
- BIIB 25.1B
- FTV 26.3B
- IPO Year
- BIIB 1991
- FTV N/A
- Fundamental
- Price
- BIIB $159.26
- FTV $79.16
- Analyst Decision
- BIIB Buy
- FTV Buy
- Analyst Count
- BIIB 25
- FTV 14
- Target Price
- BIIB $258.57
- FTV $87.82
- AVG Volume (30 Days)
- BIIB 1.6M
- FTV 2.7M
- Earning Date
- BIIB 10-30-2024
- FTV 01-29-2025
- Dividend Yield
- BIIB N/A
- FTV 0.40%
- EPS Growth
- BIIB 10.05
- FTV 7.50
- EPS
- BIIB 11.06
- FTV 2.50
- Revenue
- BIIB $9,607,500,000.00
- FTV $6,195,200,000.00
- Revenue This Year
- BIIB N/A
- FTV $4.13
- Revenue Next Year
- BIIB N/A
- FTV $4.43
- P/E Ratio
- BIIB $14.41
- FTV $31.62
- Revenue Growth
- BIIB N/A
- FTV 3.06
- 52 Week Low
- BIIB $153.62
- FTV $66.15
- 52 Week High
- BIIB $268.30
- FTV $87.10
- Technical
- Relative Strength Index (RSI)
- BIIB 35.47
- FTV 62.78
- Support Level
- BIIB $158.44
- FTV $77.74
- Resistance Level
- BIIB $165.29
- FTV $79.80
- Average True Range (ATR)
- BIIB 3.42
- FTV 1.04
- MACD
- BIIB 1.04
- FTV 0.24
- Stochastic Oscillator
- BIIB 44.34
- FTV 84.25
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About FTV Fortive Corporation
Fortive is a diversified industrial technology firm with a broad portfolio of mission-critical products and services that include field solutions, product realization, health, and sensing technologies. The company serves a wide range of end markets, including manufacturing, utilities, medical, and electronics. Fortive generated roughly $6.1 billion in revenue in 2023.